Ann: Mesoblast Phase 3 CLBP Trial Completes Enrollment, page-206

Dead or alive is a binary outcome. 10 patients receiving Remestemcel-L survived, at a time when about 80 percent of patients on ventilators were dying.

No, it wasn't a RCT. Yes, there could have been something special about our patients other than the fact that they received Remestemcel-L. No, it isn't proof. But it if Remestemcel-L didn't contribute to this striking difference in mortality, it would be an incredible coincidence. This, along with other promising trials with stem cells, is why I am incredibly confident that our trial will be successful. (Look at the Pluristem compassionate use results for more encouraging evidence, albeit not "proof.") Common sense.

And don't lecture me on statistics. I graduated college in the top 1 percent of my class with a major in mathematics, and earned multiple graduate degrees that included courses in statistics.




.